The direct costs of treating human visceral leishmaniasis in Brazil
Abstract INTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost. The aim of this study was to estimate the direct costs of therapies recommended by the Ministry of Health (MH) for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
|
| Series: | Revista da Sociedade Brasileira de Medicina Tropical |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000400478&lng=en&tlng=en |
| _version_ | 1818554214415073280 |
|---|---|
| author | Tália Santana Machado de Assis Dian Carlos Pinheiro Rosa Eliane de Morais Teixeira Gláucia Cota André Luís Ferreira Azeredo-da-Silva Guilherme Werneck Ana Rabello |
| author_facet | Tália Santana Machado de Assis Dian Carlos Pinheiro Rosa Eliane de Morais Teixeira Gláucia Cota André Luís Ferreira Azeredo-da-Silva Guilherme Werneck Ana Rabello |
| author_sort | Tália Santana Machado de Assis |
| collection | DOAJ |
| description | Abstract INTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost. The aim of this study was to estimate the direct costs of therapies recommended by the Ministry of Health (MH) for VL treatment in Brazil. METHODS: The analytical perspective used was that adopted by the Brazilian Public Health System. Three drugs and four regimens were included: 1) N-methyl glucamine antimoniate intramuscularly at 20mg per kg per day for 30 days; 2) N-methyl glucamine antimoniate intravenously at 20mg per kg per day for 30 days; 3) amphotericin B deoxycholate at 1mg per kg per day for 21 days; and 4) liposomal amphotericin B at 3mg per kg per day for a 7 days treatment. RESULTS: The estimated direct costs of treatment for an adult patient using N-methylglucamine antimoniate administered via the intramuscular and intravenous routes were USD 418.52 and USD 669.40, respectively. The estimated cost of treatment with amphotericin B deoxycholate was USD 1,522.70. Finally, the estimated costs of treatment with liposomal amphotericin B were USD 659.79, and USD 11,559.15 using the price adopted by the WHO and the Drug Regulation Board, respectively. CONCLUSIONS: This analysis indicates the economic feasibility of replacing N-methyl glucamine antimoniate with liposomal amphotericin B, which allows a shorter treatment period with less toxicity compared with other treatments, provided that the purchase value used by the WHO and transferred to the MH is maintained. |
| first_indexed | 2024-12-12T09:36:26Z |
| format | Article |
| id | doaj.art-ec4a7df59fd0496f893848ba3bd6f62a |
| institution | Directory Open Access Journal |
| issn | 1678-9849 |
| language | English |
| last_indexed | 2024-12-12T09:36:26Z |
| publisher | Sociedade Brasileira de Medicina Tropical (SBMT) |
| record_format | Article |
| series | Revista da Sociedade Brasileira de Medicina Tropical |
| spelling | doaj.art-ec4a7df59fd0496f893848ba3bd6f62a2022-12-22T00:28:42ZengSociedade Brasileira de Medicina Tropical (SBMT)Revista da Sociedade Brasileira de Medicina Tropical1678-984950447848210.1590/0037-8682-0133-2017S0037-86822017000400478The direct costs of treating human visceral leishmaniasis in BrazilTália Santana Machado de AssisDian Carlos Pinheiro RosaEliane de Morais TeixeiraGláucia CotaAndré Luís Ferreira Azeredo-da-SilvaGuilherme WerneckAna RabelloAbstract INTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost. The aim of this study was to estimate the direct costs of therapies recommended by the Ministry of Health (MH) for VL treatment in Brazil. METHODS: The analytical perspective used was that adopted by the Brazilian Public Health System. Three drugs and four regimens were included: 1) N-methyl glucamine antimoniate intramuscularly at 20mg per kg per day for 30 days; 2) N-methyl glucamine antimoniate intravenously at 20mg per kg per day for 30 days; 3) amphotericin B deoxycholate at 1mg per kg per day for 21 days; and 4) liposomal amphotericin B at 3mg per kg per day for a 7 days treatment. RESULTS: The estimated direct costs of treatment for an adult patient using N-methylglucamine antimoniate administered via the intramuscular and intravenous routes were USD 418.52 and USD 669.40, respectively. The estimated cost of treatment with amphotericin B deoxycholate was USD 1,522.70. Finally, the estimated costs of treatment with liposomal amphotericin B were USD 659.79, and USD 11,559.15 using the price adopted by the WHO and the Drug Regulation Board, respectively. CONCLUSIONS: This analysis indicates the economic feasibility of replacing N-methyl glucamine antimoniate with liposomal amphotericin B, which allows a shorter treatment period with less toxicity compared with other treatments, provided that the purchase value used by the WHO and transferred to the MH is maintained.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000400478&lng=en&tlng=enTherapeuticsCostsCost analysisVisceral leishmaniasis |
| spellingShingle | Tália Santana Machado de Assis Dian Carlos Pinheiro Rosa Eliane de Morais Teixeira Gláucia Cota André Luís Ferreira Azeredo-da-Silva Guilherme Werneck Ana Rabello The direct costs of treating human visceral leishmaniasis in Brazil Revista da Sociedade Brasileira de Medicina Tropical Therapeutics Costs Cost analysis Visceral leishmaniasis |
| title | The direct costs of treating human visceral leishmaniasis in Brazil |
| title_full | The direct costs of treating human visceral leishmaniasis in Brazil |
| title_fullStr | The direct costs of treating human visceral leishmaniasis in Brazil |
| title_full_unstemmed | The direct costs of treating human visceral leishmaniasis in Brazil |
| title_short | The direct costs of treating human visceral leishmaniasis in Brazil |
| title_sort | direct costs of treating human visceral leishmaniasis in brazil |
| topic | Therapeutics Costs Cost analysis Visceral leishmaniasis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000400478&lng=en&tlng=en |
| work_keys_str_mv | AT taliasantanamachadodeassis thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT diancarlospinheirorosa thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT elianedemoraisteixeira thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT glauciacota thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT andreluisferreiraazeredodasilva thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT guilhermewerneck thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT anarabello thedirectcostsoftreatinghumanvisceralleishmaniasisinbrazil AT taliasantanamachadodeassis directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT diancarlospinheirorosa directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT elianedemoraisteixeira directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT glauciacota directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT andreluisferreiraazeredodasilva directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT guilhermewerneck directcostsoftreatinghumanvisceralleishmaniasisinbrazil AT anarabello directcostsoftreatinghumanvisceralleishmaniasisinbrazil |